Abstract: The present invention relates to useful methods of treating Acute Myeloid Leukemia (AML) in a human. in the presence of gene mutations.

Abstract: Provided herein are methods and therapeutic combinations useful in the treatment of venetoclax-resistant Acute Myeloid Leukemia and of venetoclax-sensitive Acute Myeloid Leukemia.

Abstract: A user equipment (UE) registers on a first Public Land Mobile Network (PLMN) and, while in an idle mode, receives a Multimedia Broadcast Multicast Services (MBMS) service. The UE determines whether to perform a periodic network reselection search for a higher priority PLMN while in the idle mode, wherein the UE determines whether to perform the periodic network reselection search based on reception of the MBMS service. The UE may postpone the periodic network reselection search for a period of time while the UE receives the MBMS service in the idle mode. The UE may postpone the periodic network reselection search for a period of time while the UE receives the MBMS service in the idle mode. The UE may interleave the periodic network reselection search with the reception of transmission bursts of the MBMS service, the search being performed on frequencies other than that of the MBMS transmission.

Abstract: Disclosed are methods of selecting a subject suspected of having or having leukemia, such as lymphoblast leukemia (B-ALL), for treatment with an agent that inhibits ROR1-regulated signaling activity. In some examples, cells obtained from the subject are screened for over expression of ROR1. In other examples, the cells are contacted with an agent that inhibits ROR1 signaling activity and a ROR1-regulated signaling activity is detected. An alteration in the ROR1-regulated signaling activity as compared to a control identifies the subject as one that would benefit from treatment with an agent that inhibits ROR1 signaling activity. Also disclosed are methods for identifying an agent for treating a subject with a ROR1-dependent leukemia or with a predisposition for developing a ROR1-dependent leukemia, and methods for treating or inhibiting a ROR1-dependent leukemia, such as B-ALL in a subject.

Abstract: Methods for screening cells obtained from a subject for aberrant kinase activity are disclosed. The methods include placing cells isolated from the subject in contact with a set of siRNAs, wherein each individual siRNA is at an addressable location on the array and specifically inhibits expression of a tyrosine kinase. The siRNA is introduced into the blood cells or bone marrow cells by electroporation. After introduction of the siRNA, the cells are then assayed for proliferation and/or viability as compared to a control. A decreased proliferation and/or viability of the cells as compared to a control identifies a siRNA that inhibits the proliferation and/or viability of the cells, thus identifying the tyrosine kinase having aberrant tyrosine kinase activity in the subject.